在性结肠炎治疗中,以酶屏蔽为持续的药物释放而与相关的5-ASA水凝微粒
Yuhao Jiang1, Yuan Wang2,3, Yansong Zhang2,3
1College of Life and Environmental Science, Wenzhou University, Wenzhou 325005, China.
Biomacromolecules
|October 20, 2025
概括
新的水凝微粒有效地向炎症组织输送抗结肠病药物. 这种有针对性的方法可以防止药物过早释放,并减少所需剂量,改善结肠炎的治疗.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 针对大肠炎的向药物输送面临着药物过早激活和特异性差的挑战.
- 为有效的抗结肠病药物管理开发新型载体至关重要.
研究的目的:
- 为了设计新的水凝微粒,以针对炎症提供5-氨酸 (5-ASA).
- 在大肠炎模型中评估这些微粒的稳定性,释放动力学和治疗疗效.
主要方法:
- 5-ASA对氧化藻酸盐进行共价接种,以形成SA-AP水凝微粒.
- 在模拟的胃肠道液体中描述微粒稳定性.
- 评估由结肠细菌减少酶触发的药物释放.
- 在体外粘附试验和细胞抗炎疗效研究.
- 在德克斯硫酸盐 (DSS) 诱导的小鼠结肠炎模型中进行评估.
主要成果:
- 在模拟的胃和肠道条件下,SA-AP微粒显示出高稳定性,防止过早的5-ASA释放.
- 结肠细菌减少酶在延迟阶段后启动持续的药物释放,由水凝扩散屏障控制.
- 微粒对炎症表面呈现选择性粘附,并证实了体外抗炎作用.
- 在体内,SA-AP微粒子显著降低了疾病活性,保持了结肠长度,与自由5-ASA相比,减弱了全身炎症.
- 组织学分析显示,结肠组织架构和杯状细胞得到恢复.
结论:
- 开发的SA-AP水凝微粒为针对炎症的抗结肠病药物提供了一个有前途的战略.
- 这种系统允许在结肠中持续释放药物,并将所需的5-ASA剂量减少60%,同时提高治疗结果.
- 这些发现支持这些微粒在改善结肠炎治疗和减少副作用方面的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
452
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
452
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483


